Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.WT

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Mar 02, 2021 1:06pm
188 Views
Post# 32695945

Presentation by Abdul-Amir Yassine at SPIE.PHOTONICS WEST

Presentation by Abdul-Amir Yassine at SPIE.PHOTONICS WESTAdapting to the patient: online monitoring for interstitial photodynamic therapy using machine learning

Presenter/Author Abdul-Amir Yassine
Univ. of Toronto (Canada)
 
Author Lothar D. Lilge
Univ. Health Network (Canada)
 
Author Vaughn Betz
Univ. of Toronto (Canada)
 
Abstract
 
Treatment planning is of utmost importance in interstitial photodynamic therapy, as it predicts the required light delivery to the target volume in the upcoming treatment. However, it remains a major challenge due to uncertainties such as the tissue optical properties and the concentration of the photosensitizer and oxygen. Any small difference in these parameters from the assumed values during planning can significantly affect the outcome of the actual treatment. This work introduces a machine learning model to quickly recover the true optical properties during the treatment and re-optimize the source powers to attain the desired tumor coverage.
 
<< Previous
Bullboard Posts
Next >>